Zobrazeno 1 - 8
of 8
pro vyhledávání: '"M. A. Nahir"'
Autor:
Alexandra Balbir-Gurman, Kochava Toledano, Doron Markovits, Ludmila Guralnik, M. A. Nahir, Alexander Rozin, Yolanda Braun-Moscovici, Yonatan Butbul-Aviel
Publikováno v:
Rheumatology International. 33:1495-1504
Rituximab (RTX) is a chimeric anti-CD20 antibody, approved for rheumatoid arthritis (RA) patients who failed anti-Tumor Necrosis Factor therapy. It has been used occasionally for life-threatening autoimmune diseases (AID). We report our center experi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9db0dd15c684021ecc69e8dd822d9e5d
https://doi.org/10.1007/s00296-012-2587-x
https://doi.org/10.1007/s00296-012-2587-x
Publikováno v:
Annals of the Rheumatic Diseases. 75:1103.3-1104
Background Patients (pts) with systemic sclerosis (SSc) experience higher mortality rates. Objectives To assess the mortality and causes of death in SSc pts9 cohort at our center. Methods The data were retracted from the Rambam EUSTAR database (220 p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a6356869729eb840599ba5c9c51e4d96
https://doi.org/10.1136/annrheumdis-2016-eular.2460
https://doi.org/10.1136/annrheumdis-2016-eular.2460
Autor:
Yolanda Braun-Moscovici, Alexandra Balbir-Gurman, Alexander Rozin, Doron Melamed, M. A. Nahir, Doron Markovits, Zohar Keren
Publikováno v:
Clinical immunology (Orlando, Fla.). 133(1)
Cytokines and chemokines are key regulatory molecules involved in rheumatoid arthritis (RA). B-cell depletion therapy improves RA clinically but its mechanism is not completely understood. One possible mechanism for this therapy is the modification o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f9d90e2768468a2cd5f88ef044f1f1f8
https://pubmed.ncbi.nlm.nih.gov/19632157
https://pubmed.ncbi.nlm.nih.gov/19632157
Autor:
Y. Braun-Moscovici, Alexandra Balbir-Gurman, Doron Markovits, Daniel Schapira, Daniela Militianu, M. A. Nahir, Alexander Rozin
We read with interest the letters: “Is parenteral methotrexate worth trying?” by Osman and Mulherin1 and “Intramuscular methotrexate in inflammatory rheumatic disease” by Burbage, Gupta, and Lim.2 We would like to present our findings, which
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28f572c6b299292a36edde45a6092cec
https://europepmc.org/articles/PMC1754195/
https://europepmc.org/articles/PMC1754195/
Autor:
J P, Pelletier, M, Yaron, B, Haraoui, P, Cohen, M A, Nahir, D, Choquette, I, Wigler, I A, Rosner, A D, Beaulieu
Publikováno v:
Arthritis and rheumatism. 43(10)
To evaluate the efficacy and safety of diacerein, a drug with interleukin-1beta--inhibitory activity in vitro, in patients with knee osteoarthritis (OA).A total of 484 patients fulfilling the American College of Rheumatology criteria for knee OA were
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::0da008a6f8339d2238d8b7fc775bd31e
https://pubmed.ncbi.nlm.nih.gov/11037895
https://pubmed.ncbi.nlm.nih.gov/11037895
Autor:
K. Toledano, Alexandra Balbir-Gurman, Alexander Rozin, R. Beshara, M. A. Nahir, Doron Markovits, Amir Dagan, Yehuda Chowers, S. Ben Horin, A. Saffouri, Yolanda Braun-Moscovici
Publikováno v:
Annals of the Rheumatic Diseases. 72:A442.3-A443
Background In patients (pts) with RA and other autoimmune diseases the immunogenicity during infliximab (INF) or adalimumab (ADA) therapy lead to the r loss of response. Increasing the drug dose or shortening the re-treatment intervals has economical
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a41c21ead922ced39ddb37f4286c27d1
https://doi.org/10.1136/annrheumdis-2013-eular.1334
https://doi.org/10.1136/annrheumdis-2013-eular.1334
Autor:
M. A. Nahir, Amir Dagan, Doron Markovits, Rema Bishara, Ludmila Guralnik, Alexander Rozin, Emilia Hardak, Alexandra Balbir-Gurman, Yolanda Braun-Moscovici, K. Toledano, A. Solomonov, Mordechai Yigla
Publikováno v:
Annals of the Rheumatic Diseases. 72:A503.3-A503
Background Two RCT and several open-labeled studies demonstrated various efficacy of cyclophosphamide (CYC) for treatment of Systemic sclerosis-associated interstitial lung disease (SSc-ILD) with follow up for 1-4 years. Objectives To analyze the cha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::58d9f3d4a1521f1e024ebf45a8557236
https://doi.org/10.1136/annrheumdis-2013-eular.1512
https://doi.org/10.1136/annrheumdis-2013-eular.1512
Publikováno v:
The Laryngoscope. 99(3)
Central nervous system involvement in systemic lupus erythematosus is frequently occult, may be the presenting sign, and is a bad prognostic indicator. At present, there is no reliable, sensitive laboratory test for the evaluation and diagnosis of su
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c07c5ec21eb8d2ed661efdd8eacd9cd
https://pubmed.ncbi.nlm.nih.gov/2918803
https://pubmed.ncbi.nlm.nih.gov/2918803